Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
J Viral Hepat. 2013 Jul;20(7):470-7. doi: 10.1111/jvh.12047. Epub 2013 Apr 12.
IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were infected with HCV genotype 6 were commenced on 48 weeks of combination pegylated interferon and ribavirin therapy. Response to therapy, profiles of haemoglobin changes and platelet counts during therapy and their associations with IL28B rs8099917 and ITPA rs1127354 polymorphisms were analysed. The overall sustained virologic response (SVR) rate was 91.7%. 18 patients (30.0%) required a reduction in ribavirin dosage. The distribution of IL28B rs8099917 TT/TG genotypes and ITPA rs1127354 CC/CA genotypes were in Hardy-Weinberg equilibrium. IL28B rs8099917 TT genotype, when compared to TG genotype, was significantly associated with an increased SVR rate (96.2% and 62.5%, respectively) and was the only clinical parameter that predicted SVR (P = 0.014). The same significant association was observed when analysing allelic frequencies (T vs G, P = 0.001). ITPA rs1127354 CA genotype, when compared to CC genotype, was associated with lesser degree of anaemia throughout therapy (P < 0.05 for all time points). ITPA polymorphisms showed no association with changes in platelet count throughout therapy (P > 0.05 for all time points) and was not associated with SVR (P = 0.640). In chronic HCV genotype 6 infection, IL28B polymorphisms were associated with response to therapy. ITPA polymorphisms influenced the degree of anaemia but not thrombocytopenia during therapy.
IL28B 和肌苷三磷酸酶（ITPA）多态性分别能够预测慢性丙型肝炎病毒（HCV）感染治疗的反应和利巴韦林相关贫血的程度。然而，它们在慢性 HCV 基因型 6 治疗中的作用尚未确定。60 例感染 HCV 基因型 6 的患者开始接受 48 周的聚乙二醇干扰素联合利巴韦林治疗。分析了治疗反应、治疗期间血红蛋白变化和血小板计数特征及其与 IL28B rs8099917 和 ITPA rs1127354 多态性的关系。总的持续病毒学应答（SVR）率为 91.7%。18 例（30.0%）需要减少利巴韦林剂量。IL28B rs8099917 TT/TG 基因型和 ITPA rs1127354 CC/CA 基因型的分布符合 Hardy-Weinberg 平衡。与 TG 基因型相比，IL28B rs8099917 TT 基因型与较高的 SVR 率显著相关（分别为 96.2%和 62.5%），并且是唯一预测 SVR 的临床参数（P = 0.014）。分析等位基因频率时也观察到相同的显著相关性（T 对 G，P = 0.001）。与 CC 基因型相比，ITPA rs1127354 CA 基因型在整个治疗期间与贫血程度较轻相关（所有时间点 P <0.05）。ITPA 多态性与整个治疗过程中血小板计数的变化无关（所有时间点 P > 0.05），与 SVR 无关（P = 0.640）。在慢性 HCV 基因型 6 感染中，IL28B 多态性与治疗反应相关。ITPA 多态性影响治疗期间贫血的程度，但不影响血小板减少症。
